MPE Masterclass 2021
The MPE Masterclass 2021 was held virtually and included lectures on myeloma and AL amyloidosis diagnosis and treatment, discussions on access challenges across Europe, presentations on the impact of COVID-19 on the patient community, and workshops to support the capacity of patient organizations.
Watch below the recordings of the presentations given on the 2nd and 3rd July 2021.


MPE Masterclass 2021 | Welcome message

MPE Masterclass - A welcome message from Dr María Victoria Mateos

MPE Masterclass - A welcome message from Dr Mohamad Mohty

MPE Masterclass 2021 | The early detection and diagnosis of MGUS and SMM

MPE Masterclass 2021 | Immunotherapy in the treatment of myeloma and AL amyloidosis

Masterclass 2021 | COVID 19 and the effect on the treatment for myeloma and AL amyloidosis patients

MPE Masterclass 2021 | New developments and controversies in the myeloma treatment pathway

MPE Masterclass 2021 |Developments in AL amyloidosis diagnostic centres of expertise

MPE Masterclass 2021 | Palliative Care and quality of life

MPE Masterclass 2021 | MPE members response to and resiliency during COVID 19. Poland

MPE Masterclass 2021 | MPE members response to and resiliency during COVID 19. Israel

MPE Masterclass 2021 | Panel discussion on Minimal Residual Disease (MRD). Hans Scheurer

MPE Masterclass 2021 | Panel discussion on Minimal Residual Disease (MRD). Hans Jacobs

MPE Masterclass 2021 | Panel discussion on Minimal Residual Disease (MRD). Paula van Hennik

MPE Masterclass 2021 | Access to new treatments in CEE countries

MPE Masterclass 2021 | Myeloma related diseases

MPE Masterclass 2021 | Fundraising for patient groups and collaboration with industry

Annual Masterclass 2020
The MPE Annual General Meeting (AGM) 2020 was cancelled due to the COVID-19 outbreak. The educational programme planned to be held in the Annual Masterclass was replaced by the MPE Webinars series.


MPE AGM 2020 - Webinar on Myeloma and AL amyloidosis treatment updates

MPE AGM 2020 - Webinar on reimbursement and Health Technology Assessment (HTA) in Europe

MPE AGM2020 webinar series - Big data, the Harmony example

Watch the webinar on personalised medicines in myeloma and AL amyloidosis

Minimal Residual Disease (MRD) in myeloma and related diseases

Webinar on the impact of myeloma and AL amyloidosis in carers

Annual Masterclass 2019


MPE AGM 2019 outtakes

Myeloma Treatment Updates

Surrogate end-points in myeloma and AL amyloidosis

Measuring and utilising quality of life

AL Amyloidosis

The role of CAR-T

Annual Masterclass 2018


MPE Capacity Building Programme

Community Advisory Boards and case studies of MPE member groups

Rehabilitation, self-care and quality of life

Journey to a professional and empowered advocate

Clinical trials design and study endpoints

Myeloma related diseases

Drug access and affordability

Coping with a chronic disease

Update on diagnosis and treatment of AL amyloidosis

Annual Masterclass 2017


MPE dialogues - “Where are we now in myeloma and how does the future look like?”

Welcome, introductions and driving throught the conference

The European Atlas of Access to Myeloma Treatment

Update on current diagnosis and treatment of myeloma and related diseases

Clinical trials and drugs under development in myeloma and AL Amyloidosis

Treatment of myeloma in the light of access barriers

Patient advocate development strategies: how can an umbrella organisation help you

Annual Masterclass 2016


Treating myeloma. An update on the current myeloma treatment guidelines

Myeloma and Amyloidosis 101

What is multiple myeloma associated amyloidosis?

Advocacy session 1 – Patient involvement in clinical research

Welcome and introductions

The MPE Atlas: myeloma UK case study

Evidence based advocacy: implementing the MPE Atlas

Atlas Coaching Programme

Myeloma beyond C.R.A.B. An update on the current mueloma diagnosis guidelines
